TraderKnowsVanda Pharmaceuticals週三表示，已拒絕了英國Cycle Pharmaceutical和合同製造商Future Pak的收購要約，認爲這兩項提議都低估了這家美國製藥公司的價值。
這是Vanda第三次拒絕Future Pak的收購要約。自今年四月收到Future Pak的首次收購提議後，Vanda採取了股東權利計劃，即“毒丸計劃”，以降低被敵意收購的風險。
該計劃旨在防止任何實體在未經董事會批准的情況下，獲得超過10%的股份。
上週，Future Pak在其最終收購嘗試中，提高了收購要約中的現金部分，將其提升至每股8.50至9.00美元，並維持先前提出的每股約4.27美元的或有價值權。
Cycle Pharma本月初提出的每股8美元現金收購要約，估值爲4.66億美元。
Vanda董事會週三拒絕了這兩項提議，並聲明：“兩者都嚴重低估了Vanda的價值，不符合公司及其股東的最佳利益。”
The market carries risks, and investment should be cautious. This article does not constitute personal investment advice and has not taken into account individual users' specific investment goals, financial situations, or needs. Users should consider whether any opinions, viewpoints, or conclusions in this article are suitable for their particular circumstances. Investing based on this is at one's own responsibility.
收購（Acquisition）是指一家企業或個人通過購買另一家企業的股權或資產來獲取對目標企業的控制權或所有權的過程。
TraderKnows is a financial media platform, with information displayed coming from public networks or uploaded by users. TraderKnows does not endorse any trading platform or variety. We bear no responsibility for any trading disputes or losses arising from the use of this information. Please be aware that displayed information may be delayed, and users should independently verify it to ensure its accuracy.
